timi天美传孟若羽

Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator Riociguat in Healthy Young Chinese Male Non-Smokers and Smokers: Results of a Randomized, Double-Blind, Placebo-Controlled Study.

Clin Pharmacokinet. Accepted.

Zhao X

Cui YM

5.053

Metformin versus insulin for gestational diabetes mellitus: a meta-analysis.

 Br J Clin Pharmacol.
2015 Apr 29. 
 [Epub ahead of print]

Zhao LP

Zhou Y

3.878

Impact of pharmacist intervention on antibiotic use and prophylactic antibiotic use in urology clean operations.

2015;40(4):404-8.

Zhou Y

Cui YM

1.668

Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Single- and multiple-dose Once-daily Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Chinese Patients With Type 2 Diabetes Mellitus.

Clin Ther. 2015;37(7):1493-1502.

Zhao X

Cui YM

2.731

Efficacy and tolerability of canagliflozin as add-on to metformin in the treatment of type 2 diabetes mellitus: a meta-analysis.

Eur J Clin Pharmacol.
2015 Aug 19.

Yang T

Cui Y

2.966

Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial.

JAMA.
2015 Apr 7;313(13):1325-35.

Huo Y

-

35.289

Folic acid supplementation with and without vitamin B6 and revascularization risk: a meta-analysis of randomized controlled trials.

2014 Aug;33(4):603-12.

Qin X

Huo Y

4.476

Population pharmacokinetic study of cyclosporine in the hematopoietic stem cell transplant recipients.

 2013 Jul;51(7):568-75.

Zhou Y

Cui YM

1.044

Identification of PEAR1 SNPs and their influences on the variation in prasugrel pharmacodynamics.

Pharmacogenomics. 2013 Jul;14(10):1179-89.

Xiang Q

Cui YM

3.425

Folic acid supplementation and cancer risk: A meta-analysis of randomized controlled trials.

Int J Cancer.
2013 Sep 1;133(5):1033-41.

Qin X

Huo Y

5.007

Pharmacokinetics, safety, and tolerability of exenatide once weekly in Chinese patients with type 2 diabetes mellitus.

J Diabetes. 2013 ;5(2):127-35.

Cui YM

Guo XH

2.349

Integration of genetic and clinical data to analyze pharmacokinetic profile of mycophenolic acid in a population of Chinese patients with glomerular disease.

Int. Res. J. Pharm. Pharmacol.
2013; 3(2): 19-28.

Xiang Q,
Yu F

Cui YM
Wang HY

1.323

The Influence of UGT 2B7, UGT1A8, MDR1, ALDH, ADH, CYP3A4 and CYP3A5 genetic polymorphisms on the pharmacokinetics of silodosin in healthy Chinese volunteers.

2013;28(3):239-43.

Wang ZN, Xiang Q

Cui YM

2.863

Factors underlying the association of body mass index with serum ALT in Chinese hypertensive adults without known hepatic diseases.

J Zhejiang Univ Sci B.
2013 Aug; 14(8): 743–748.

Zhang Y

Huo Y

1.293

The influence of MDR1 G2677T/A genetic polymorphisms on the pharmacokinetics of repaglinide in healthy Chinese volunteers.

Pharmacology, 2012;89:105-110.

Xiang Q

Cui YM

1.603

MTHFR C677T and MTR A2756G polymorphisms and the homocysteine lowering efficacy of different doses of folic acid in hypertensive Chinese adults.

Nutr J.
2012; 11-2.

Qin X

Huo Y

4.196

Effect of folic acid intervention on the change of serum folate level in hypertensive Chinese adults: do methylenetetrahydrofolate reductase and methionine synthase gene polymorphisms affect therapeutic responses?

Pharmacogenet Genomics. 2012;22(6):421-8.

Qin X

Huo Y

3.608

Pharmacokinetics and pharmacodynamics of single and multiple doses of prasugrel in healthy native Chinese subjects.

Acta Pharmacol Sin. 2012; 33(11):1395-1400.

Wang ZN

Cui YM

2.354

Population pharmacokinetics and pharmacodynamics of bivalirudin in young healthy Chinese volunteers.

Acta Pharmacol Sin. 2012; 33(11):1387-94.

Zhang DM

Cui YM

2.354

A single-center, randomized, open-label, dose-escalation study to evaluate the pharmacokinetics of tacrine analogue octahydrogenacridine succinate tablets in healthy Chinese subjects.

Biol Pharm Bull. 2012;35(9):1502-8.

Zhao X

Cui YM

1.849

Effect of folic acid intervention on ALT concentration in hypertensives without known hepatic disease: a randomized, double-blind, controlled trial.

Eur J Clin Nutr. 2012;66(5):541-8.

Qin X

Huo Y

2.756

Pharmacokinetics, pharmacodynamics, tolerability and safety of single doses of bivalirudin in healthy chinese subjects.

Biol Pharm Bull. 2011; 34: 1841-1848.

Zhang DM

Cui YM

1.657

Safety and Pharmacokinetic Studies of Silodosin, a New α1A-Adrenoceptor Selective Antagonist, in Healthy Chinese Male Subjects.

Biol Pharm Bull, 2011, 34, 1240-1245.

Zhou Y

Cui YM

1.657

Tolerance and pharmacokinetics of single-dose intravenous hemoporfin in healthy volunteers.

Acta Pharmacol Sin. 2011;32(12):1549-54.

Sun PH

Cui YM

1.953

Effect of CYP2D6, CYP3A5 and MDR1 Genetic Polymorphisms on the Pharmacokinetics of Risperidone and its Active Moiety.

J Clin Pharmacol. 2010;50:659-66.

Xiang Q

Cui YM

3.063

Safety, pharmacokinetics and pharmacodynamics of single and multiple dose of rivaroxaban – an oral, direct Factor Xa inhibitor – in healthy Chinese subjects.

Br J Clin Pharmacol.
2009; 66: 77-88.

Zhao X

Cui YM

3.246

Determination of silodosin in human plasma by liquid chromatography-tandem mass spectrometry.

J Chromatogr B Analyt Technol Biomed Life Sci. 2009; 877: 3724-3728.

Zhao X

Cui YM

2.777

Exenatide pharmacokinetics in healthy Chinese subjects.

International Journal of clinical pharmacology and therapeutics.
2008, 46, 459-465.

Zhao X

Cui YM

3.128

Atomoxetine Pharmacokinetics in Healthy Chinese Subjects and effect of the CYP2D6*10 allele.

Br J Clin Pharmacol. 2007;64:445-9.

Cui YM

Cui YM

2.681

Liquid chromatography tandem mass spectrometry assay to determine the pharmacokinetics of aildenafil in human plasma.

J Pharm Biomed Anal. 2007;44:231-5.

Wang J

Cui YM

2.761